BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 13,353 Shares of Repligen Corporation $RGEN

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in shares of Repligen Corporation (NASDAQ:RGENFree Report) by 4.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 315,102 shares of the biotechnology company’s stock after selling 13,353 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.56% of Repligen worth $40,093,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. KBC Group NV increased its holdings in shares of Repligen by 14.9% in the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 329 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of Repligen during the 1st quarter worth about $132,000. GAMMA Investing LLC grew its stake in Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 274 shares during the last quarter. XTX Topco Ltd raised its holdings in Repligen by 34.2% in the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock valued at $1,646,000 after acquiring an additional 3,295 shares during the period. Finally, TD Asset Management Inc raised its holdings in Repligen by 10.9% in the 1st quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company’s stock valued at $6,511,000 after acquiring an additional 5,014 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 1.8%

RGEN stock opened at $124.35 on Monday. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The business has a 50-day simple moving average of $122.50 and a 200 day simple moving average of $132.49. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.00 billion, a PE ratio of -497.38, a price-to-earnings-growth ratio of 2.29 and a beta of 1.05.

Repligen (NASDAQ:RGENGet Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same period in the prior year, the business earned $0.40 earnings per share. Repligen’s quarterly revenue was up 14.8% compared to the same quarter last year. Sell-side analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the business’s stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. HC Wainwright reissued a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Evercore ISI decreased their price objective on Repligen from $140.00 to $130.00 and set an “in-line” rating on the stock in a report on Tuesday, July 8th. Barclays began coverage on Repligen in a report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 target price for the company. Finally, Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price for the company in a research report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $169.45.

Get Our Latest Research Report on Repligen

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.